EUVIMEDOpdag EUVIMED
Randomisierte kontrollierte StudieOpen access · CC BY 4.0

Efficacy and Safety of Intralymphatic Immunotherapy With Grass Allergoid and Microcrystalline Tyrosine: A Double‐Blind Randomised Placebo‐Controlled Trial

Lara Šošić iD, Stephan C Flory, Claudia C V Lang iD, Emma C Widmer, Alexandra Chabot, Johannes M Schmid iD, Tobias Andermatt, David Melillo iD, Bjarke Hviid-Vyff iD, Maibritt Mardahl iD, Peter Schmid-Grendelmeier iD, Thomas M Kündig iD and 2 more

Allergy · 2026-11 · 81 (11) · 4051-4064

DOI: 10.1111/all.70463 ↗

At a glance

Randomisierte kontrollierte Studie in Allergy, published online on 2026-07-29. Written by Lara Šošić and 13 co-authors. Institution: Department of Dermatology, University of Zurich, Zurich, Switzerland. Major MEDLINE topics: Desensitization, Immunologic, Poaceae, Rhinitis, Allergic, Seasonal, Pollen. 55 references. The full text is freely available (open access, CC BY 4.0). Funded by: Stiftung für wissenschaftliche Forschung an der Universität Zürich, Innovation Fund Denmark, University Hospital Zurich Innovationspool.

AbstractSubjectsBibliografiske oplysningerCiteRelated studies

Abstract (original language)

Background

Intralymphatic immunotherapy (ILIT) has been investigated for two decades in small clinical trials, typically using native allergens adsorbed to aluminium hydroxide (alum). This randomised, double‐blind, placebo‐controlled study evaluated the safety and efficacy of ILIT with a grass pollen allergoid formulated with microcrystalline tyrosine (MCT).

Methods

Sixty adults with grass pollen–induced allergic rhinoconjunctivitis (ARC) were randomised to receive ILIT with grass allergoid (equivalent to 60 ng Phl p 5; n = 31) or placebo ( n = 29). Three ultrasound‐guided injections (100 μL) were administered into inguinal lymph nodes at 4‐week intervals in early 2022. The primary endpoint was the combined symptom and medication score (cSMS), recorded daily during the 2022 and 2023 grass pollen seasons. Secondary endpoints included safety, Rhinitis Quality of Life Questionnaire (RQLQ), serology, spirometry, fractional exhaled nitric oxide (FeNO), and skin‐prick testing (SPT). An open‐label extension, in which the placebo participants received active ILIT, was conducted in 2024.

Results

ILIT was well tolerated, with no severe adverse events (SAEs). Mild local reactions (wheal, erythema, swelling) occurred after 50 of 93 active injections (53.8%), and three moderate reactions (3.2%) were reported. In the placebo group, one mild and no moderate reactions occurred. No allergen‐specific systemic reactions were observed. Compared with placebo, ILIT reduced cSMS by 33% in 2022 ( p > 0.05) and 50% in 2023 ( p < 0.05). RQLQ improved with relative reductions of 22% and 13% ( p > 0.05), respectively.

Conclusion

ILIT with a grass pollen allergoid formulated with MCT was well tolerated and associated with clinically relevant reductions in symptom and medication use in grass pollen–induced ARC. In this small study cohort, ILIT proved to be efficient and safe, but further optimisation of dosing regimens should follow.

Subjects

MeSH terms (MEDLINE)

Desensitization, ImmunologicPoaceaeRhinitis, Allergic, SeasonalPollenAllergensAllergoidsHumansFemaleAdultDouble-Blind MethodMaleTreatment OutcomeInjections, IntralymphaticMiddle AgedImmunoglobulin EYoung Adult

Author keywords

adjuvantallergen‐specific immunotherapyallergic rhinoconjunctivitisgrass pollen allergoidintralymphatic immunotherapymicrocrystalline tyrosine

Substances

AllergensImmunoglobulin EAllergoids

Authors and institutions

  • Department of Dermatology, University of Zurich, Zurich, Switzerland.
  • Department of Dermatology, University Hospital Zurich, Zurich, Switzerland.
  • Department of Clinical Medicine, Aarhus University, Aarhus, Denmark.
  • Department of Respiratory Diseases and Allergy, Aarhus University, Aarhus, Denmark.
  • Data-Set-Go ApS, Silkeborg, Denmark.

ORCID profiles: Lara Šošić, Claudia C V Lang, Johannes M Schmid, David Melillo, Bjarke Hviid-Vyff, Maibritt Mardahl, Peter Schmid-Grendelmeier, Thomas M Kündig, Hans Jürgen Hoffmann, Pål Johansen

Funding

  • Stiftung für wissenschaftliche Forschung an der Universität Zürich
  • Innovation Fund Denmark
  • University Hospital Zurich Innovationspool
  • Foundation for Research in Science and the Humanities
  • Innovationsfonden

Cite

APA

Šošić, L., Flory, S. C., Lang, C. C. V., Widmer, E. C., Chabot, A., Schmid, J. M., Andermatt, T., Melillo, D., Hviid-Vyff, B., Mardahl, M., Schmid-Grendelmeier, P., Kündig, T. M., Hoffmann, H. J., & Johansen, P. (2026). Efficacy and Safety of Intralymphatic Immunotherapy With Grass Allergoid and Microcrystalline Tyrosine: A Double‐Blind Randomised Placebo‐Controlled Trial. Allergy, 81(11), 4051-4064. https://doi.org/10.1111/all.70463

Vancouver

Šošić L, Flory SC, Lang CCV, Widmer EC, Chabot A, Schmid JM, et al. Efficacy and Safety of Intralymphatic Immunotherapy With Grass Allergoid and Microcrystalline Tyrosine: A Double‐Blind Randomised Placebo‐Controlled Trial. Allergy. 2026;81(11):4051-4064. doi:10.1111/all.70463

BibTeX
@article{oi2026,
  author = {Šošić, Lara and Flory, Stephan C and Lang, Claudia C V and Widmer, Emma C and Chabot, Alexandra and Schmid, Johannes M and Andermatt, Tobias and Melillo, David and Hviid-Vyff, Bjarke and Mardahl, Maibritt and Schmid-Grendelmeier, Peter and Kündig, Thomas M and Hoffmann, Hans Jürgen and Johansen, Pål},
  title = {Efficacy and Safety of Intralymphatic Immunotherapy With Grass Allergoid and Microcrystalline Tyrosine: A Double‐Blind Randomised Placebo‐Controlled Trial},
  journal = {Allergy},
  year = {2026},
  volume = {81},
  number = {11},
  pages = {4051--4064},
  doi = {10.1111/all.70463}
}
Start for free →